Effects of Clara cell 10 (CC10) protein on symptoms and signs of allergic rhinitis.
(2009) In Annals of Allergy, Asthma & Immunology 102(1). p.51-56- Abstract
- BACKGROUND: The Clara cell 10 (CC10) protein is produced by the airway epithelium. Reduced levels of CC10 are associated with allergic rhinitis and asthma. In experimental models, treatment with the CC10 protein may reduce features of airway inflammation. OBJECTIVES: To examine whether or not topical treatment with recombinant human CC10 (rhCC10) affects symptoms and signs of allergic rhinitis in a pollen season model. METHODS: Out of the pollen season, patients with allergic rhinitis received treatment with rhCC10, 0.56 mg per nasal cavity, once daily for 7 days in a double-blinded, placebo-controlled, crossover design. During this period, individualized allergen challenges were given once daily. Symptoms and peak nasal inspiratory flow... (More)
- BACKGROUND: The Clara cell 10 (CC10) protein is produced by the airway epithelium. Reduced levels of CC10 are associated with allergic rhinitis and asthma. In experimental models, treatment with the CC10 protein may reduce features of airway inflammation. OBJECTIVES: To examine whether or not topical treatment with recombinant human CC10 (rhCC10) affects symptoms and signs of allergic rhinitis in a pollen season model. METHODS: Out of the pollen season, patients with allergic rhinitis received treatment with rhCC10, 0.56 mg per nasal cavity, once daily for 7 days in a double-blinded, placebo-controlled, crossover design. During this period, individualized allergen challenges were given once daily. Symptoms and peak nasal inspiratory flow (PNIF) were recorded daily in the morning, 10 minutes after challenge, and in the evening. Mean recordings of the last 3 days of the challenge series were used in the analysis. Nasal lavages were performed at the end of each challenge period, and eosinophil cationic protein, myeloperoxidase, and alpha2-macroglobulin levels were measured as indices of eosinophil and neutrophil activity and plasma exudation, respectively. RESULTS: Recombinant human CC10 did not affect allergen-induced morning, postchallenge, or evening symptoms compared with placebo. Morning, postchallenge, and evening PNIF were not improved by rhCC10. No statistically significant differences were observed between rhCC10 and placebo for any of the lavage fluid indices. CONCLUSIONS: Repeated nasal administrations of rhCC10 protein, in the present dose, do not exert antiallergic effects in seasonal allergic rhinitis. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1302736
- author
- Widegren, Henrik LU ; Andersson, Morgan LU and Greiff, Lennart LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Allergy, Asthma & Immunology
- volume
- 102
- issue
- 1
- pages
- 51 - 56
- publisher
- Elsevier
- external identifiers
-
- wos:000262333300010
- pmid:19205286
- scopus:59449098503
- ISSN
- 1081-1206
- language
- English
- LU publication?
- yes
- id
- 2d2f9905-a4f8-4819-b9ba-bce5ad38e19f (old id 1302736)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19205286?dopt=Abstract
- date added to LUP
- 2016-04-04 07:20:27
- date last changed
- 2022-03-30 22:13:05
@article{2d2f9905-a4f8-4819-b9ba-bce5ad38e19f,
abstract = {{BACKGROUND: The Clara cell 10 (CC10) protein is produced by the airway epithelium. Reduced levels of CC10 are associated with allergic rhinitis and asthma. In experimental models, treatment with the CC10 protein may reduce features of airway inflammation. OBJECTIVES: To examine whether or not topical treatment with recombinant human CC10 (rhCC10) affects symptoms and signs of allergic rhinitis in a pollen season model. METHODS: Out of the pollen season, patients with allergic rhinitis received treatment with rhCC10, 0.56 mg per nasal cavity, once daily for 7 days in a double-blinded, placebo-controlled, crossover design. During this period, individualized allergen challenges were given once daily. Symptoms and peak nasal inspiratory flow (PNIF) were recorded daily in the morning, 10 minutes after challenge, and in the evening. Mean recordings of the last 3 days of the challenge series were used in the analysis. Nasal lavages were performed at the end of each challenge period, and eosinophil cationic protein, myeloperoxidase, and alpha2-macroglobulin levels were measured as indices of eosinophil and neutrophil activity and plasma exudation, respectively. RESULTS: Recombinant human CC10 did not affect allergen-induced morning, postchallenge, or evening symptoms compared with placebo. Morning, postchallenge, and evening PNIF were not improved by rhCC10. No statistically significant differences were observed between rhCC10 and placebo for any of the lavage fluid indices. CONCLUSIONS: Repeated nasal administrations of rhCC10 protein, in the present dose, do not exert antiallergic effects in seasonal allergic rhinitis.}},
author = {{Widegren, Henrik and Andersson, Morgan and Greiff, Lennart}},
issn = {{1081-1206}},
language = {{eng}},
number = {{1}},
pages = {{51--56}},
publisher = {{Elsevier}},
series = {{Annals of Allergy, Asthma & Immunology}},
title = {{Effects of Clara cell 10 (CC10) protein on symptoms and signs of allergic rhinitis.}},
url = {{http://www.ncbi.nlm.nih.gov/pubmed/19205286?dopt=Abstract}},
volume = {{102}},
year = {{2009}},
}